Prelude Therapeutics (PRLD) Stock Forecast, Price Target & Predictions
PRLD Stock Forecast
Prelude Therapeutics stock forecast is as follows: an average price target of $6.25 (represents a 125.63% upside from PRLD’s last price of $2.77) and a rating consensus of 'Sell', based on 3 wall street analysts offering a 1-year stock forecast.
PRLD Price Target
PRLD Analyst Ratings
Prelude Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 10, 2024 | Robert Burns | H.C. Wainwright | $5.00 | $5.17 | -3.29% | 80.51% |
Jun 20, 2024 | Peter Lawson | Barclays | $3.00 | $3.87 | -22.48% | 8.30% |
Mar 13, 2024 | Reni Benjamin | JMP Securities | $7.00 | $4.62 | 51.52% | 152.71% |
Nov 17, 2022 | - | H.C. Wainwright | $15.00 | $7.70 | 94.81% | 441.52% |
Nov 15, 2022 | - | Morgan Stanley | $10.00 | $8.10 | 23.46% | 261.01% |
Prelude Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 2 | 3 |
Avg Price Target | $5.00 | $4.00 | $5.00 |
Last Closing Price | $2.77 | $2.77 | $2.77 |
Upside/Downside | 80.51% | 44.40% | 80.51% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 10, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
Jun 20, 2024 | Barclays | Equal-Weight | Underweight | Downgrade |
Dec 19, 2023 | Morgan Stanley | Equal-Weight | Underweight | Downgrade |
Nov 15, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Feb 28, 2022 | Barclays | - | Equal-Weight | Downgrade |
Prelude Therapeutics Financial Forecast
Prelude Therapeutics Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Prelude Therapeutics EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Prelude Therapeutics Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-33.71M | $-33.71M | $-32.58M | $-31.06M | $-36.90M | $-35.74M | $-32.58M |
High Forecast | $-33.71M | $-33.71M | $-32.58M | $-31.06M | $-36.90M | $-35.00M | $-32.58M |
Low Forecast | $-33.71M | $-33.71M | $-32.58M | $-31.06M | $-36.90M | $-37.23M | $-32.58M |
Surprise % | - | - | - | - | - | - | - |
Prelude Therapeutics SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Prelude Therapeutics EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.45 | $-0.45 | $-0.43 | $-0.41 | $-0.49 | $-0.47 | $-0.43 |
High Forecast | $-0.45 | $-0.45 | $-0.43 | $-0.41 | $-0.49 | $-0.46 | $-0.43 |
Low Forecast | $-0.45 | $-0.45 | $-0.43 | $-0.41 | $-0.49 | $-0.49 | $-0.43 |
Surprise % | - | - | - | - | - | - | - |
Prelude Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
STTK | Shattuck Labs | $3.81 | $12.00 | 214.96% | Buy |
PEPG | PepGen | $9.48 | $29.50 | 211.18% | Buy |
MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
PRLD | Prelude Therapeutics | $2.77 | $6.25 | 125.63% | Sell |
FHTX | Foghorn Therapeutics | $9.72 | $18.00 | 85.19% | Buy |
PHVS | Pharvaris | $20.92 | $38.50 | 84.03% | Buy |
CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
NRIX | Nurix Therapeutics | $24.80 | $27.57 | 11.17% | Buy |
KYMR | Kymera Therapeutics | $46.08 | $51.10 | 10.89% | Buy |
CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
PRLD Forecast FAQ
Is Prelude Therapeutics a good buy?
No, according to 3 Wall Street analysts, Prelude Therapeutics (PRLD) is considered a 'Sell'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of PRLD's total ratings.
What is PRLD's price target?
Prelude Therapeutics (PRLD) average price target is $6.25 with a range of $3 to $10, implying a 125.63% from its last price of $2.77. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Prelude Therapeutics stock go up soon?
According to Wall Street analysts' prediction for PRLD stock, the company can go up by 125.63% (from the last price of $2.77 to the average price target of $6.25), up by 261.01% based on the highest stock price target, and up by 8.30% based on the lowest stock price target.
Can Prelude Therapeutics stock reach $4?
PRLD's average twelve months analyst stock price target of $6.25 supports the claim that Prelude Therapeutics can reach $4 in the near future.
What is Prelude Therapeutics's current price target trend?
1 Wall Street analyst forecast a $5 price target for Prelude Therapeutics (PRLD) this month, up 80.51% from its last price of $2.77. Compared to the last 3 and 12 months, the average price target increased by 44.40% and increased by 80.51%, respectively.
What are Prelude Therapeutics's analysts' financial forecasts?
Prelude Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-105M (high $-104M, low $-107M), average SG&A $0 (high $0, low $0), and average EPS is $-1.389 (high $-1.379, low $-1.408). PRLD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-131M (high $-131M, low $-131M), average SG&A $0 (high $0, low $0), and average EPS is $-1.73 (high $-1.73, low $-1.73).